Daniel Lee, CEO of Aperion Biologics Inc., is set to break into the European biotechnology market with its new Z-Lig ligament reconstruction device. Aperion Biologics , one of several San Antonio-based bioscience firms that had an opportunity to pitch to potential investors on Thursday during the World Stem Cell Summit's inaugural RegMed Capital Conference, is only weeks away from rolling out its initial product.